Computational selection of antibody-drug conjugate targets for breast cancer

Oncotarget

Volumn 7, Issue 3, 2016, Pages 2555-2571

  Fauteux, François ^a   Hill, Jennifer J ^a,b   Jaramillo, Maria L ^a,b   Pan, Youlian ^a   Phan, Sieu ^a   Famili, Fazel ^a   O'Connor McCourt, Maureen ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b Montreal Centre   (Canada)

Author keywords

ADC; Drug target; Ensemble classification; Feature selection; Microarray

Indexed keywords

ANTIBODY CONJUGATE; CELL PROTEIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CELL MEMBRANE; CLASSIFICATION ALGORITHM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERNEL METHOD; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; TRIPLE NEGATIVE BREAST CANCER; BIOLOGY; BREAST NEOPLASMS; CLASSIFICATION; DRUG DELIVERY SYSTEM; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOCONJUGATES; TUMOR CELLS, CULTURED;

EID: 84962273565     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6679     Document Type: Article

References (99)

1. Ginsburg GS and McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends in biotechnology. 2001; 19:491-496.
2. Scott AM, Wolchok JD and Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12:278-287.
3. Reichert JM and Dhimolea E. The future of antibodies as cancer drugs. Drug discovery today. 2012; 17:954-963.
4. Goswami S, Wang W, Arakawa T and Ohtake S. Developments and challenges for mAb-based therapeutics. Antibodies. 2013; 2:452-500.
5. Sievers EL and Senter PD. Antibody-drug conjugates in cancer therapy. Annual review of medicine. 2013; 64:15-29.
6. Sassoon I and Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013; 1045:1-27.
7. Bander NH. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol. 2013; 1045:29-40.
8. Gashaw I, Ellinghaus P, Sommer A and Asadullah K. What makes a good drug target? Drug discovery today. 2011; 16:1037-1043.
9. Loging W, Harland L and Williams-Jones B. High-throughput electronic biology: mining information for drug discovery. Nat Rev Drug Discov. 2007; 6:220-230.
10. Desany B and Zhang Z. Bioinformatics and cancer target discovery. Drug discovery today. 2004; 9:795-802.
11. Yang Y, Adelstein SJ and Kassis AI. Target discovery from data mining approaches. Drug discovery today. 2009; 14:147-154.
12. Mathur R and Weiner G. (2012). Picking the optimal target for antibody-drug conjugates. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting, pp. 103-107.
13. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS and Cheung VG. Genetic analysis of genome-wide variation in human gene expression. Nature. 2004; 430:743-747.
14. Churchill GA. Fundamentals of experimental design for cDNA microarrays. Nat Genet. 2002; 32 Suppl:490-495.
15. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013; 41(Database issue):D991-995.
16. Affymetrix. (2014). GeneChip Human Genome U133 Plus 2.0 Array (http://www.affymetrix.com).
17. Rung J and Brazma A. Reuse of public genome-wide gene expression data. Nat Rev Genet. 2013; 14:89-99.
18. Zhu Y, Davis S, Stephens R, Meltzer PS and Chen Y. GEOmetadb: powerful alternative search engine for the Gene Expression Omnibus. Bioinformatics. 2008; 24:2798-2800.
19. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:2784-2795.
20. Larranaga P, Calvo B, Santana R, Bielza C, Galdiano J, Inza I, Lozano JA, Armananzas R, Santafe G, Perez A and Robles V. Machine learning in bioinformatics. Briefings in bioinformatics. 2006; 7:86-112.
21. Saeys Y, Inza I and Larranaga P. A review of feature selection techniques in bioinformatics. Bioinformatics. 2007; 23:2507-2517.
22. Student. The probable error of a mean. Biometrika. 1908:1-25.
23. Fisher RA. (1925). Statistical Methods for Research Workers. (Edinburgh: Oliver and Boyd).
24. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology. 2004; 3:3.
25. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015.
26. Cohen J. The earth is round (p<.05). American psychologist. 1994; 49:997.
27. Lin M, Lucas Jr HC and Shmueli G. Research commentary-too big to fail: large samples and the p-value problem. Information Systems Research. 2013; 24:906-917.
28. Díaz-Uriarte R and De Andres SA. Gene selection and classification of microarray data using random forest. BMC Bioinformatics. 2006; 7:3.
29. Guyon I, Weston J, Barnhill S and Vapnik V. Gene selection for cancer classification using support vector machines. Machine Learning. 2002; 46:389-422.
30. Schmid F and Schmidt A. Nonparametric estimation of the coefficient of overlapping-theory and empirical application. Computational statistics & data analysis. 2006; 50:1583-1596.
31. Abramson IS. On bandwidth variation in kernel estimates-a square root law. The Annals of Statistics. 1982:1217-1223.
32. Silverman BW. (1986). Density estimation for statistics and data analysis. (New York: Chapman & Hall/CRC).
33. International Agency for Research on Cancer. World cancer report 2014. Geneva: WHO. 2014.
34. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.
35. Perrino E, Steiner M, Krall N, Bernardes GJ, Pretto F, Casi G and Neri D. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 2014; 74:2569-2578.
36. Teicher BA and Chari RV. Antibody conjugate therapeutics: challenges and potential. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:6389-6397.
37. Weigelt B, Peterse JL and van"t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005; 5:591-602.
38. Fidler IJ. The pathogenesis of cancer metastasis: the'seed and soil'hypothesis revisited. Nature Reviews Cancer. 2003; 3:453-458.
39. Chaffer CL and Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331:1559-1564.
40. Polyak K and Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9:265-273.
41. Baguley BC. Multidrug resistance in cancer. Methods Mol Biol. 2010; 596:1-14.
42. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117:927-939.
43. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature cell biology. 2008; 10:593-601.
44. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, McNeil E, Moy C, Wegrzyn R, Auger K, Hardwicke MA and Wooster R. Molecular target class is predictive of in vitro response profile. Cancer Res. 2010; 70:3677-3686.
45. Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R, Doroshow J, Weinstein JN and Pommier Y. Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res. 2010; 70:2191-2203.
46. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000; 24:227-235.
47. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ and Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005; 33:e175.
48. Gray KA, Yates B, Seal RL, Wright MW and Bruford EA. Genenames.org: the HGNC resources in 2015. Nucleic Acids Res. 2014.
49. Barrell D, Dimmer E, Huntley RP, Binns D, O'Donovan C and Apweiler R. The GOA database in 2009-an integrated Gene Ontology Annotation resource. Nucleic Acids Res. 2009; 37:D396-403.
50. UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 2014.
51. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68:9280-9290.
52. Rostami S, Qazi I and Sikorski R. The clinical landscape of antibody-drug conjugates. J Antibody Drug Conjugates. 2014.
53. Zarin DA, Tse T, Williams RJ, CaliffRM and Ide NC. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011; 364:852-860.
54. U.S. National Institutes of Health. (2000). ClinicalTrials.gov (http://www.clinicaltrials.gov).
55. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA and Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015; 6:22496-22512. doi: 10.18632/oncotarget.4318.
56. Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB and Finkler NJ. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer immunology, immunotherapy: CII. 2003; 52:243-248.
57. Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M and Coleman RE. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2000; 11:735-741.
58. Sadelain M, Brentjens R and Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Current opinion in immunology. 2009; 21:215-223.
59. Park TS, Rosenberg SA and Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011; 29:550-557.
60. Rosenberg SA and Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348:62-68.
61. Onitilo AA, Engel JM, Greenlee RT and Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical medicine & research. 2009; 7:4-13.
62. Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, Luis E, Zhong F, Bheddah S, Koeppen H, Gogineni A, Ross S, Polakis P and Mallet W. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007; 67:4924-4932.
63. Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, Sugaya M, So T, Sugio K and Yasumoto K. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006; 66:4922-4928.
64. Brennen WN, Isaacs JT and Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012; 11:257-266.
65. Hamson EJ, Keane FM, Tholen S, Schilling O and Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clinical applications. 2014; 8:454-463.
66. Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ and Adolf GR. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:4584-4592.
67. Shiang C, Qi Y, Wang B, Broom B and Pusztai L. P3-17-01: ApoE and Its Receptors (LRP8, VLDLR) Function as Growth Signals for Triple-Negative Breast Cancer and Represent a Novel Therapeutic Target. Cancer Research. 2011; 71(24 Supplement):P3-17-01-P13-17-01.
68. Nyren-Erickson EK, Jones JM, Srivastava DK and Mallik S. A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. Biochimica et biophysica acta. 2013; 1830:4445-4455.
69. Duhachek-Muggy S and Zolkiewska A. ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer. BMC cancer. 2015; 15:93.
70. Li H, Duhachek-Muggy S, Dubnicka S and Zolkiewska A. Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. Breast cancer research and treatment. 2013; 139:691-703.
71. Kalluri R and Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6:392-401.
72. Maier T, Guell M and Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS letters. 2009; 583:3966-3973.
73. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W and Selbach M. Global quantification of mammalian gene expression control. Nature. 2011; 473:337-342.
74. Wilhelm M, Schlegl J, Hahne H, Moghaddas Gholami A, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, Mathieson T, Lemeer S, Schnatbaum K, Reimer U, Wenschuh H, Mollenhauer M, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014; 509:582-587.
75. Maric G, Rose AA, Annis MG and Siegel PM. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and therapy. 2013; 6:839-852.
76. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y and Weinstein JN. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC genomics. 2009; 10:277.
77. von Eschenbach AC and Buetow K. Cancer informatics vision: caBIG. Cancer informatics. 2006; 2:22-24.
78. R Core Team. (2014). R: A Language and Environment for Statistical Computing. (Vienna, Austria: R Foundation for Statistical Computing).
79. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome biology. 2004; 5:R80.
80. Gautier L, Cope L, Bolstad BM and Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20:307-315.
81. Hubbell E, Liu W-M and Mei R. Robust estimators for expression analysis. Bioinformatics. 2002; 18(12):1585-1592.
82. Stajich JE, Block D, Boulez K, Brenner SE, Chervitz SA, Dagdigian C, Fuellen G, Gilbert JG, Korf I, Lapp H, Lehvaslaiho H, Matsalla C, Mungall CJ, Osborne BI, Pocock MR, Schattner P, et al. The Bioperl toolkit: Perl modules for the life sciences. Genome Res. 2002; 12(10):1611-1618.
83. Duda RO, Hart PE and Stork DG. (2001). Pattern classification. (New York; Chichester England: Wiley).
84. Li T, Zhang C and Ogihara M. A comparative study of feature selection and multiclass classification methods for tissue classification based on gene expression. Bioinformatics. 2004; 20:2429-2437.
85. Storey JD. The positive false discovery rate: A Bayesian interpretation and the q-value. Annals of Statistics. 2003:2013-2035.
86. Eddelbuettel D. (2013). Seamless R and C++ Integration with Rcpp. (New York: Springer).
87. Meyer D, Dimitriadou E, Hornik K, Weingessel A and Leisch F. (2014). e1071: Misc Functions of the Department of Statistics, TU Wien. R package version 1.6-2.
88. Kim J-H. Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap. Computational statistics & data analysis. 2009; 53:3735-3745.
89. Braga-Neto UM and Dougherty ER. Is cross-validation valid for small-sample microarray classification? Bioinformatics. 2004; 20:374-380.
90. Hornik K, Buchta C and Zeileis A. Open-source machine learning: R meets Weka. Computational Statistics. 2009; 24:225-232.
91. Breiman L. Bagging predictors. Machine Learning. 1996; 24:123-140.
92. Quinlan JR. (1992). Learning with continuous classes. Proceedings of the 5th Australian joint Conference on Artificial Intelligence. (Singapore: World Scientific), pp. 343-348.
93. Aha DW, Kibler D and Albert MK. Instance-based learning algorithms. Machine Learning. 1991; 6:37-66.
94. John GH and Langley P. (1995). Estimating continuous distributions in Bayesian classifiers. Proceedings of the Eleventh conference on Uncertainty in artificial intelligence. (San Francisco: Morgan Kaufmann), pp. 338-345.
95. Breiman L. Random forests. Machine Learning. 2001; 45:5-32.
96. Platt JC. (1999). Fast training of support vector machines using sequential minimal optimization. Advances in kernel methods. (Cambridge: MIT press), pp. 185-208.
97. Tan AC and Gilbert D. Ensemble machine learning on gene expression data for cancer classification. Applied bioinformatics. 2003; 2(3 Suppl):S75-83.
98. Neville J and Jensen D. (2000). Iterative classification in relational data. Proc AAAI-2000 Workshop on Learning Statistical Models from Relational Data, pp. 13-20.
99. Bates D, Mächler M, Bolker BM and Walker SC. Fitting linear mixed-effects models using lme4. Journal of Statistical Software. 2015; 67.